SEC Filings

Form S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Document Outline
Entire Document (7286.4 KB)
Subdocument 1 - S-1 - S-1
Page 1 - As filed with the Securities and Exchange Commission on September 16, 2014.
Page 2 - PRELIMINARY PROSPECTUS
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - PRT-201
Page 6 - Secondary Endpoints
Page 7 - Additional PRT-201 Indications
Page 8 - Phase 3 endpoints same as our Phase 2 trial.
Page 9 - Corporate Information
Page 10 - N/A
Page 11 - THE OFFERING
Page 12 - N/A
Page 13 - SUMMARY FINANCIAL DATA
Page 14 - N/A
Page 15 - RISK FACTORS
Page 16 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 17 - We have never generated any revenue from product sales and may never be profitable.
Page 18 - Risks Related to Clinical Development, Regulatory Review and Approval of Our Product
Page 19 - Clinical development is a lengthy and expensive process with an uncertain outcome due to many factor
Page 20 - If clinical trials of PRT-201 or any additional product candidates fail to demonstrate safety and ef
Page 21 - We may be unable to obtain regulatory approval for PRT-201 or any additional product candidates unde
Page 22 - We may face difficulty in enrolling patients for clinical trials.
Page 23 - If we experience any of a number of possible unforeseen events in connection with clinical trials of
Page 24 - Any product for which we obtain FDA approval will be subject to extensive ongoing regulatory require
Page 25 - PRT-201 may cause undesirable side effects or have other properties that could delay or prevent thei
Page 26 - Even if we obtain and maintain approval for PRT-201 or additional product candidates from the FDA, w
Page 27 - We may not be able to comply with requirements of foreign jurisdictions in conducting trials outside
Page 28 - Risks Related to Commercialization of Our Product
Page 29 - Even if PRT-201 or any additional product candidates receive regulatory approval, they may fail to a
Page 30 - PRT-201 or any additional product candidates for which we intend to seek approval as biologic produc
Page 31 - Risks Related to Dependence on Third Parties
Page 32 - We rely on third parties to conduct some or all aspects of our product manufacturing, protocol devel
Page 33 - We rely on third parties to conduct, supervise and monitor our clinical trials. If these third parti
Page 34 - We may seek to form partnerships in the future with respect to PRT-201 or any additional product can
Page 35 - inter partes
Page 36 - Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure
Page 37 - Third-party claims of intellectual property infringement or misappropriation may prevent or delay ou
Page 38 - If we are unable to adequately protect our proprietary technology, or obtain and maintain issued pat
Page 39 - ex parte
Page 40 - We may be subject to claims challenging the inventorship or ownership of our patents and other intel
Page 41 - We will not seek to protect our intellectual property rights in all jurisdictions throughout the wor
Page 42 - Some of our intellectual property may have been discovered through government funded programs and th
Page 43 - Changes in United States patent law could diminish the value of patents in general, thereby impairin
Page 44 - Numerous factors may limit any potential competitive advantage provided by our intellectual property
Page 45 - We will need to significantly increase the size of our organization, and we may experience difficult
Page 46 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 47 - If we engage in acquisitions in the future, we will incur a variety of costs and we may never realiz
Page 48 - Our business and operations would suffer in the event of system failures.
Page 49 - N/A
Page 50 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 51 - There has been no public market for our common stock prior to this offering, and you may not be able
Page 52 - Raising additional funds through debt or equity financing could be dilutive and may cause the market
Page 53 - If securities analysts do not publish research or reports about our business or if they downgrade ou
Page 54 - Future sales and issuances of our common stock or rights to purchase common stock, including pursuan
Page 55 - We will incur significant increased costs as a result of operating as a public company, and our mana
Page 56 - We could be subject to securities class action litigation.
Page 57 - N/A
Page 58 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 59 - USE OF PROCEEDS
Page 60 - CAPITALIZATION
Page 61 - Series D Convertible Preferred Stock
Page 62 - Anti-dilution protection for Series D convertible preferred stock.
Page 63 - N/A
Page 64 - DILUTION
Page 65 - N/A
Page 66 - N/A
Page 67 - SELECTED FINANCIAL DATA
Page 68 - N/A
Page 69 - MANAGEMENT'S DISCUSSION AND ANALYSIS
Page 70 - Financial Overview
Page 71 - General and Administrative Expenses
Page 72 - Critical Accounting Policies and Significant Judgments and Estimates
Page 73 - Derivative Instruments
Page 74 - Compensation Stock Compensation
Page 75 - Determination of the Fair Value of Common Stock on Grant Dates
Page 76 - Methods Used to Allocate Our Enterprise Value to Classes of Securities
Page 77 - Research and Development Expenses.
Page 78 - Research and Development Expenses.
Page 79 - Series D Financing
Page 80 - Cash Flows
Page 81 - Off-Balance Sheet Arrangements
Page 82 - Contractual Obligations
Page 83 - BUSINESS
Page 84 - Our Strengths
Page 85 - Safety profile supports approval.
Page 86 - Commercialize PRT-201 directly in the United States.
Page 87 - N/A
Page 88 - Established Medical Need
Page 89 - The procedures are not always successful in restoring patency.
Page 90 - PRT-201
Page 91 - PRT-201 Treatment Inhibits Stenosis Formation
Page 92 - Primary Unassisted Patency All AVFs
Page 93 - Primary Unassisted Patency Radiocephalic AVFs
Page 94 - Reduction in Risk of Primary Unassisted Patency Loss vs. Placebo Brachiocephalic AVFs
Page 95 - Secondary and other endpoints
Page 96 - Unassisted Maturation Radiocephalic AVFs
Page 97 - Average Procedure Rate to Restore/Maintain Patency Including Registry Data (p-Value vs. Placebo)
Page 98 - Use for hemodialysis.
Page 99 - Phase 1/2 AVF Clinical Trial
Page 100 - Preclinical Development
Page 101 - Peripheral Artery Disease
Page 102 - Sales and Marketing
Page 103 - Patents
Page 104 - Competition
Page 105 - Approval process
Page 106 - N/A
Page 107 - U.S. Patent Term Restoration
Page 108 - Post-approval requirements
Page 109 - Fast track designation and accelerated approval
Page 110 - Biosmilars
Page 111 - European Union EMA process
Page 112 - Data and market exclusivity
Page 113 - Sales and marketing
Page 114 - Other laws and regulatory processes
Page 115 - Legal Proceedings
Page 116 - MANAGEMENT
Page 117 - George A. Eldridge
Page 118 - Todd Foley
Page 119 - Dmitry Kobyzev, Ph.D.
Page 120 - Board Committees
Page 121 - Compensation Committee
Page 122 - Compensation Committee Interlocks and Insider Participation
Page 123 - EXECUTIVE AND DIRECTOR COMPENSATION
Page 124 - Base Salary
Page 125 - Timothy P. Noyes
Page 126 - Daniel P. Gottlieb
Page 127 - Outstanding Equity Awards at Fiscal Year End
Page 128 - Employee Benefit and Stock Plans
Page 129 - Amendment and Termination
Page 130 - Available Shares
Page 131 - Stock Appreciation Rights
Page 132 - Qualified Performance-Based Awards
Page 133 - Change of Control
Page 134 - Allocation of Awards; Plan Benefits.
Page 135 - Withdrawal
Page 136 - Amount of Benefits
Page 137 - N/A
Page 138 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 139 - Series D Preferred Stock Financing
Page 140 - Related Party Transactions Policy
Page 141 - PRINCIPAL STOCKHOLDERS
Page 142 - N/A
Page 143 - N/A
Page 144 - N/A
Page 145 - DESCRIPTION OF CAPITAL STOCK
Page 146 - Warrants
Page 147 - Action by Written Consent; Special Meetings of Stockholders.
Page 148 - Authorized but Unissued Shares.
Page 149 - SHARES ELIGIBLE FOR FUTURE SALE
Page 150 - Rule 144
Page 151 - Rule 701
Page 152 - MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO
Page 153 - Distributions on Common Stock
Page 154 - Gain on Disposition of Common Stock
Page 155 - Foreign Account Tax Compliance Act
Page 156 - UNDERWRITING
Page 157 - Commissions and Discounts
Page 158 - NASDAQ Market Listing
Page 159 - Electronic Distribution
Page 160 - Notice to Prospective Investors in the United Kingdom
Page 161 - Notice to Prospective Investors in the Netherlands
Page 162 - N/A
Page 163 - LEGAL MATTERS
Page 164 - Proteon Therapeutics, Inc.
Page 165 - Proteon Therapeutics, Inc.
Page 166 - N/A
Page 167 - N/A
Page 168 - Proteon Therapeutics, Inc.
Page 169 - N/A
Page 170 - 1. Organization and operations
Page 171 - Notes to Financial Statements (Continued)
Page 172 - Notes to Financial Statements (Continued)
Page 173 - Notes to Financial Statements (Continued)
Page 174 - Notes to Financial Statements (Continued)
Page 175 - Notes to Financial Statements (Continued)
Page 176 - Notes to Financial Statements (Continued)
Page 177 - Notes to Financial Statements (Continued)
Page 178 - Notes to Financial Statements (Continued)
Page 179 - Notes to Financial Statements (Continued)
Page 180 - Notes to Financial Statements (Continued)
Page 181 - Notes to Financial Statements (Continued)
Page 182 - Notes to Financial Statements (Continued)
Page 183 - Notes to Financial Statements (Continued)
Page 184 - Notes to Financial Statements (Continued)
Page 185 - Notes to Financial Statements (Continued)
Page 186 - Notes to Financial Statements (Continued)
Page 187 - Notes to Financial Statements (Continued)
Page 188 - Notes to Financial Statements (Continued)
Page 189 - Notes to Financial Statements (Continued)
Page 190 - Notes to Financial Statements (Continued)
Page 191 - Notes to Financial Statements (Continued)
Page 192 - Notes to Financial Statements (Continued)
Page 193 - Notes to Financial Statements (Continued)
Page 194 - Notes to Financial Statements (Continued)
Page 195 - Notes to Financial Statements (Continued)
Page 196 - Shares
Page 197 - PART II
Page 198 - Item 15. Recent Sales of Unregistered Securities
Page 199 - Item 16. Exhibits and Financial Statement Schedules.
Page 200 - N/A
Page 201 - (b) Financial Statement Schedules
Page 202 - bona fide
Page 203 - SIGNATURES
Page 204 - EXHIBIT INDEX
Page 205 - N/A
Subdocument 2 - EX-3.1 - EX-3.1
Page 1 - Exhibit 3.1
Page 2 - General Corporation Law
Page 3 - General
Page 4 - Dividends
Page 5 - Subsections 1.1
Page 6 - Series A Original Issue Price
Page 7 - Series D Liquidation Price
Page 8 - Series B Liquidation Price
Page 9 - Liquidation Amount
Page 10 - Major Holder
Page 11 - first
Page 12 - Directors
Page 13 - Optional Conversion
Page 14 - Series A Conversion Price
Page 15 - Subsection 4.1.1
Page 16 - Conversion Time
Page 17 - Effect of Conversion
Page 18 - Series D Purchase Agreement
Page 19 - Subsection 4.1.2
Page 20 - No Adjustment of Conversion Price
Page 21 - Subsection 4.4.3
Page 22 - Determination of Consideration
Page 23 - Multiple Closing Dates
Page 24 - Adjustments for Other Dividends and Distributions
Page 25 - Subsections 4.4
Page 26 - Mandatory Conversion
Page 27 - Section 5
Page 28 - Special Mandatory Conversion.
Page 29 - Subsection 4.2
Page 30 - Subsection 4.1
Page 31 - Waiver
Page 32 - ELEVENTH
Page 33 - IN WITNESS WHEREOF
Subdocument 3 - EX-3.3 - EX-3.3
Page 1 - Exhibit 3.3
Page 2 - TABLE OF CONTENTS
Page 3 - TABLE OF CONTENTS
Page 4 - TABLE OF CONTENTS
Page 5 - BYLAWS
Page 6 - Section 6.
Page 7 - Section 8.
Page 8 - Section 11.
Page 9 - (c)
Page 10 - Section 14.
Page 11 - (b)
Page 12 - Section 19.
Page 13 - (c)
Page 14 - Section 24.
Page 15 - Section 28.
Page 16 - Section 29.
Page 17 - Section 33.
Page 18 - Section 36.
Page 19 - (c)
Page 20 - ARTICLE IX
Page 21 - (c)
Page 22 - expenses
Page 23 - (b)
Page 24 - provided, however
Page 25 - (f)
Page 26 - (h)
Page 27 - N/A
Subdocument 4 - EX-4.2 - EX-4.2
Page 1 - Exhibit 4.2
Page 2 - TABLE OF CONTENTS
Page 3 - TABLE OF CONTENTS
Page 4 - FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT
Page 5 - Charter
Page 6 - Fully Exercising Investor
Page 7 - Preferred Stock
Page 8 - Securities Act
Page 9 - Registration Rights
Page 10 - Section 2.3
Page 11 - Section 2.2
Page 12 - provided that
Page 13 - Furnish Information
Page 14 - provided
Page 15 - Section 2.9
Page 16 - Section 2.9
Page 17 - Market Stand-off Agreement
Page 18 - Restrictions on Transfer
Page 19 - Section 2.14(c)
Page 20 - Section 3.1
Page 21 - Section 3.3
Page 22 - Management Rights Letter
Page 23 - Section 4.1
Page 24 - Employee Agreements
Page 25 - Meetings of the Board of Directors
Page 26 - Termination of Covenants
Page 27 - Notices
Page 28 - Section 2.12
Page 29 - [SIGNATURE PAGE TO THE PROTEON THERAPEUTICS, INC.
Page 30 - PROTEON THERAPEUTICS, INC.
Page 31 - PROTEON THERAPEUTICS, INC.
Page 32 - PROTEON THERAPEUTICS, INC.
Page 33 - PROTEON THERAPEUTICS, INC.
Page 34 - PROTEON THERAPEUTICS, INC.
Page 35 - PROTEON THERAPEUTICS, INC.
Page 36 - PROTEON THERAPEUTICS, INC.
Page 37 - PROTEON THERAPEUTICS, INC.
Page 38 - PROTEON THERAPEUTICS, INC.
Page 39 - PROTEON THERAPEUTICS, INC.
Page 40 - PROTEON THERAPEUTICS, INC.
Page 41 - PROTEON THERAPEUTICS, INC.
Page 42 - PROTEON THERAPEUTICS, INC.
Page 43 - PROTEON THERAPEUTICS, INC.
Page 44 - PROTEON THERAPEUTICS, INC.
Subdocument 5 - EX-4.3 - EX-4.3
Page 1 - Exhibit 4.3
Page 2 - TABLE OF CONTENTS
Page 3 - TABLE OF CONTENTS
Page 4 - N/A
Page 5 - SERIES D PREFERRED STOCK PURCHASE AGREEMENT
Page 6 - Section 1.1(b)(i)
Page 7 - Second Tranche Closing Notice
Page 8 - Section 2.1(a)
Page 9 - Third Tranche Shares
Page 10 - Section 1.1(d)
Page 11 - Section 1.1(d)
Page 12 - Section 1.7
Page 13 - Bessemer
Page 14 - Section 3.8
Page 15 - RC-AVF
Page 16 - Net Issue Election Form
Page 17 - Right of First Refusal and Co-Sale Agreement
Page 18 - Series D Price
Page 19 - Voting Agreement
Page 20 - Section 2.1(a)
Page 21 - Third Tranche Individual Purchase Shares
Page 22 - Section 2.1(b)
Page 23 - Exhibit A
Page 24 - Section 2.1(a)(ii)
Page 25 - Stock Plan
Page 26 - N/A
Page 27 - Section 4
Page 28 - Sections 3.8.1 through 3.8.4
Page 29 - Section 3.10
Page 30 - N/A
Page 31 - Section 3.15
Page 32 - Section 3.16(d)
Page 33 - ERISA
Page 34 - Employee/Consulting Agreements
Page 35 - Environmental Laws
Page 36 - N/A
Page 37 - Representations and Warranties
Page 38 - Compliance Certificate
Page 39 - Proceedings and Documents
Page 40 - Compliance Certificate
Page 41 - Minimum Aggregate Purchase Price at Third Tranche Closing
Page 42 - Representations and Warranties
Page 43 - N/A
Page 44 - N/A
Page 45 - N/A
Page 46 - [SIGNATURE PAGE TO THE PROTEON THERAPEUTICS, INC.
Page 47 - PROTEON THERAPEUTICS, INC.
Page 48 - PROTEON THERAPEUTICS, INC.
Page 49 - PROTEON THERAPEUTICS, INC.
Page 50 - PROTEON THERAPEUTICS, INC.
Page 51 - PROTEON THERAPEUTICS, INC.
Page 52 - PROTEON THERAPEUTICS, INC.
Page 53 - PROTEON THERAPEUTICS, INC.
Page 54 - PROTEON THERAPEUTICS, INC.
Page 55 - PROTEON THERAPEUTICS, INC.
Page 56 - PROTEON THERAPEUTICS, INC.
Page 57 - PROTEON THERAPEUTICS, INC.
Page 58 - PROTEON THERAPEUTICS, INC.
Page 59 - PROTEON THERAPEUTICS, INC.
Page 60 - PROTEON THERAPEUTICS, INC.
Page 61 - PROTEON THERAPEUTICS, INC.
Page 62 - PROTEON THERAPEUTICS, INC.
Page 63 - PROTEON THERAPEUTICS, INC.
Page 64 - PROTEON THERAPEUTICS, INC.
Page 65 - PROTEON THERAPEUTICS, INC.
Page 66 - PROTEON THERAPEUTICS, INC.
Page 67 - PROTEON THERAPEUTICS, INC.
Page 68 - PROTEON THERAPEUTICS, INC.
Page 69 - EXHIBITS
Subdocument 6 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - 5) Options Subject to Board approval at their next meeting you shall be entitled to a grant of optio
Subdocument 7 - EX-10.4 - EX-10.4
Page 1 - Exhibit 10.4
Page 2 - Options
Page 3 - N/A
Page 4 - By Reason of Constructive Termination
Page 5 - provided further
Page 6 - one hundred eighty
Page 7 - At-Will Employment
Page 8 - Timing of Payments
Page 9 - Assignment and Successors
Page 10 - FIRST AMENDMENT TO EMPLOYMENT AGREEMENT
Page 11 - one hundred eighty
Page 12 - Proteon Therapeutics, Inc. ( Company ):
Subdocument 8 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - Options
Page 3 - By Reason of Constructive Termination
Page 4 - provided
Page 5 - provided, however
Page 6 - At-Will Employment
Page 7 - Timing of Payments
Page 8 - Withholding
Page 9 - Entire Agreement
Page 10 - FIRST AMENDMENT TO EMPLOYMENT AGREEMENT
Page 11 - provided
Page 12 - provided, however
Subdocument 9 - EX-10.6 - EX-10.6
Page 1 - Exhibit 10.6
Page 2 - Options
Page 3 - 6-Month Tail Period
Page 4 - provided
Page 5 - provided however
Page 6 - provided
Page 7 - Tax Matters
Page 8 - Noncompetition Covenant
Page 9 - Indemnification
Page 10 - Entire Agreement
Page 11 - EXHIBIT A
Page 12 - IN WITNESS WHEREOF
Subdocument 10 - EX-10.7 - EX-10.7
Page 1 - Exhibit 10.7
Page 2 - By the Company for Cause
Page 3 - Tax Matters
Page 4 - Release Deadline
Page 5 - Severability
Page 6 - [AGE 40 and OVER FORM Put final signatory version on Proteon Letterhead]
Page 7 - Protection of Confidential Information
Page 8 - Acknowledgments; Return and Effective Date
Page 9 - I, the undersigned, having had the time to reflect, freely accept the above Agreement.
Subdocument 11 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - Yours sincerely, PROTEON THERAPEUTICS, INC. /s/ Timothy P. Noyes Name: Timothy P. Noyes Title: Presi
Subdocument 12 - EX-10.9 - EX-10.9
Page 1 - Exhibit 10.9
Page 2 - PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT
Page 3 - Additional Services
Page 4 - Change Order
Page 5 - Conforming Drug Substance
Page 6 - FDCA
Page 7 - Manufacturing Documentation
Page 8 - Project Manager
Page 9 - Replacement Drug Substance
Page 10 - ARTICLE 2
Page 11 - Project Management
Page 12 - Transfer and Engineering Runs
Page 13 - Approval of Subcontracting
Page 14 - Payment Terms
Page 15 - ARTICLE 8
Page 16 - Regulatory Authorities
Page 17 - Section 14.2.1
Page 18 - ARTICLE 11
Page 19 - ARTICLE 13
Page 20 - PROTEON Materials
Page 21 - LONZA
Page 22 - Performance
Page 23 - Indemnification Procedures
Page 24 - Disclaimer regarding Transfer and Engineering Runs
Page 25 - provided
Page 26 - Terms of Agreement
Page 27 - ARTICLE 17
Page 28 - Termination
Page 29 - Force Majeure Termination
Page 30 - Accrued Rights
Page 31 - ARTICLE 20
Page 32 - Rules
Page 33 - Headings
Page 34 - Waiver
Page 35 - IN WITNESS WHEREOF
Page 36 - Exhibit C
Page 37 - Exhibit C
Page 38 - QUALITY AGREEMENT
Page 39 - Amendment 1 to Process Development and Manufacturing Services Agreement
Page 40 - Wall Street Journal
Page 41 - N/A
Page 42 - Exhibit A-1
Page 43 - Exhibit E
Subdocument 13 - EX-10.10 - EX-10.10
Page 1 - Exhibit 10.10
Page 2 - N/A
Page 3 - N/A
Page 4 - Exhibits
Page 5 - N/A
Page 6 - ARTICLE II
Page 7 - Tenant s Parking
Page 8 - Habendum
Page 9 - Operating Expenses
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - Real Estate Taxes
Page 14 - Tenant Electricity
Page 15 - ARTICLE III
Page 16 - Roof, Exterior Wall, Floor Slab and Common Facility Repairs
Page 17 - ARTICLE V
Page 18 - Use
Page 19 - Obstructions; Items Visible from Exterior; Rules and Regulations
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - plus
Page 24 - Right of Entry
Page 25 - N/A
Page 26 - Vendors
Page 27 - ARTICLE VI
Page 28 - Uninsured Casualty
Page 29 - Award
Page 30 - ARTICLE VII
Page 31 - N/A
Page 32 - N/A
Page 33 - Landlord s Default
Page 34 - Breach
Page 35 - Tenant s Commercial General Liability Insurance
Page 36 - Tenant s Other Insurance
Page 37 - Requirements for Tenant s Insurance
Page 38 - Subtenants and Other Occupants
Page 39 - Tenant s Work
Page 40 - ARTICLE IX
Page 41 - Notice to Mortgagee and Ground Lessor
Page 42 - Assignment of Rents
Page 43 - Brokerage
Page 44 - Recording; Confidentiality
Page 45 - Status Reports and Financial Statements
Page 46 - Self-Help
Page 47 - Security Deposit
Page 48 - Late Payment
Page 49 - Waiver of Trial by Jury
Page 50 - EXHIBIT A
Page 51 - PARCEL II:
Page 52 - PARCEL III
Page 53 - Page 4
Page 54 - EXHIBIT B-1
Page 55 - Substantial Completion
Page 56 - Time of the Essence
Page 57 - Prohibition on Access by Tenant Prior to Actual Substantial Completion
Page 58 - Tenant Obligations with Respect to Tenant Delays
Page 59 - Quality and Performance of Work
Page 60 - Page 2
Page 61 - Page 3
Page 62 - EXHIBIT C
Page 63 - EXHIBIT D
Page 64 - WINDOW CLEANING
Page 65 - ELECTRICAL SERVICES
Page 66 - EXHIBIT E
Page 67 - EXHIBIT G
Page 68 - EXHIBIT H
Page 69 - Page 2
Page 70 - EXHIBIT I
Page 71 - Page 2
Page 72 - FIRST AMENDMENT TO LEASE
Page 73 - N/A
Page 74 - N/A
Page 75 - SECOND AMENDMENT TO LEASE
Page 76 - N/A
Page 77 - THIRD AMENDMENT TO LEASE
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - EXHIBIT A
Page 83 - shall be referred to as the Prevailing Market Rent. 6. Costs. Each party shall pay the costs and exp
Subdocument 14 - EX-10.11 - EX-10.11
Page 1 - Exhibit 10.11
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - IN WITNESS WHEREOF the respective parties hereto have executed this Agreement by their duly authoriz
Subdocument 15 - EX-10.12 - EX-10.12
Page 1 - Exhibit 10.12
Page 2 - N/A
Subdocument 16 - EX-10.13 - EX-10.13
Page 1 - Exhibit 10.13
Page 2 - Proteon Therapeutics, Inc.
Page 3 - Please direct all correspondence to:
Subdocument 17 - EX-10.14 - EX-10.14
Page 1 - Exhibit 10.14
Subdocument 18 - EX-10.15 - EX-10.15
Page 1 - Exhibit 10.15
Subdocument 19 - EX-10.16 - EX-10.16
Page 1 - Exhibit 10.16
Page 2 - (a)
Page 3 - (b)
Page 4 - (d)
Page 5 - (a)
Subdocument 20 - EX-10.17 - EX-10.17
Page 1 - Exhibit 10.17
Page 2 - Indemnity of Indemnitee
Page 3 - Additional Indemnity
Page 4 - Indemnification for Expenses .or a Witness
Page 5 - Section 6(a
Page 6 - Section 6(e
Page 7 - Remedies of Indemnitee
Page 8 - Section 7
Page 9 - Exception to Right of Indemnification
Page 10 - Duration of Agreement
Page 11 - Independent Counsel
Page 12 - SIGNATURE PAGE TO FOLLOW
Page 13 - IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the
Subdocument 21 - EX-10.18 - EX-10.18
Page 1 - Exhibit 10.18
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a
Page 7 - Section 6(e
Page 8 - Remedies of Indemnitee
Page 9 - Section 7
Page 10 - Exception to Right of Indemnification
Page 11 - Independent Counsel
Page 12 - Notice By Indemnitee
Page 13 - SIGNATURE PAGE TO FOLLOW
Page 14 - IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the
Subdocument 22 - EX-10.19 - EX-10.19
Page 1 - Exhibit 10.19
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a)
Page 7 - Section 6(e)
Page 8 - Remedies of Indemnitee
Page 9 - Section 7
Page 10 - Exception to Right of Indemnification
Page 11 - Independent Counsel
Page 12 - Notice By Indemnitee
Page 13 - SIGNATURE PAGE TO FOLLOW
Page 14 - SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT - FOLEY
Subdocument 23 - EX-10.20 - EX-10.20
Page 1 - Exhibit 10.20
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a)
Page 7 - Section 6(e)
Page 8 - Remedies of Indemnitee
Page 9 - Section 7
Page 10 - Exception to Right of Indemnification
Page 11 - Independent Counsel
Page 12 - Notice By Indemnitee
Page 13 - SIGNATURE PAGE TO FOLLOW
Page 14 - SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT - FRANANO
Subdocument 24 - EX-10.21 - EX-10.21
Page 1 - Exhibit 10.21
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a)
Page 7 - Section 6(e)
Page 8 - Remedies of Indemnitee
Page 9 - Section 7
Page 10 - Exception to Right of Indemnification
Page 11 - Duration of Agreement
Page 12 - Notice By Indemnitee
Page 13 - SIGNATURE PAGE TO FOLLOW
Page 14 - SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT - NOYES
Subdocument 25 - EX-10.22 - EX-10.22
Page 1 - Exhibit 10.22
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a)
Page 7 - Section 6(e)
Page 8 - Remedies of Indemnitee
Page 9 - Section 13
Page 10 - Exception to Right of Indemnification
Page 11 - Independent Counsel
Page 12 - Notice By Indemnitee
Page 13 - SIGNATURE PAGE TO FOLLOW
Page 14 - SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT - PHELPS
Subdocument 26 - EX-10.23 - EX-10.23
Page 1 - Exhibit 10.23
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a)
Page 7 - N/A
Page 8 - Remedies of Indemnitee
Page 9 - Section 7
Page 10 - Fund Indemnitors
Page 11 - Definitions
Page 12 - Section 7
Page 13 - Counterparts
Page 14 - SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT - HAINES
Subdocument 27 - EX-10.24 - EX-10.24
Page 1 - Exhibit 10.24
Page 2 - INDEMNIFICATION AGREEMENT
Page 3 - Indemnity of Indemnitee
Page 4 - Additional Indemnity
Page 5 - Indemnification for Expenses of a Witness
Page 6 - Section 6(a)
Page 7 - N/A
Page 8 - Remedies of Indemnitee
Page 9 - Section 7
Page 10 - Fund Indemnitors
Page 11 - Exception to Right of Indemnification
Page 12 - Proceeding
Page 13 - Counterparts
Page 14 - SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT -
Subdocument 28 - EX-21.1 - EX-21.1
Page 1 - EXHIBIT 21.1
Subdocument 29 - EX-23.2 - EX-23.2
Page 1 - Exhibit 23.2
Page 2 - N/A